Ladenburg Thalmann Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov has initiated coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and set a price target of $7.
December 27, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ladenburg Thalmann analyst Aydin Huseynov has initiated coverage on PMV Pharma with a Buy rating and a price target of $7.
Initiation of coverage by an analyst with a Buy rating typically indicates a positive outlook on the stock, suggesting potential upside. The announcement of a price target higher than the current market price can lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100